

Supporting Information

A First Catalyst and Solvent-Free Synthesis of 2-Arylimidazo[2,1-*b*][1,3,4]thiadiazoles: A Comparative Assessment of Greenness

Preeti Wadhwa, Tanpreet Kaur and Anuj Sharma*

Department of Chemistry
Indian Institute of Technology, Roorkee
Roorkee-247 667, India
E-mail: anujs77@gmail.com)

Table of Contents

Experimental Section	S2-S3
Spectral data of all synthesized compounds.....	S3-S8
Green metrics calculations.....	S10-S13
Copies of ¹ H and ¹³ C NMR of all compounds.....	S14-S49

Experimental Section

General. ^1H NMR spectra were recorded on a Bruker Advance[®] 500 (500 MHz) and Jeol Resonance ECX-400II (400 MHz); Chemical shifts (δ in ppm) and coupling constant (J in Hz) are calibrated either relative to internal solvent tetramethylsilane TMS ($\delta_{\text{H}} = 0.00\text{ppm}$) or CDCl_3 ($\delta_{\text{H}} = 7.26\text{ ppm}$). In the ^1H NMR data, the following abbreviations were used throughout: s = singlet, d = doublet, t = triplet, dd = double doublets, dt = double triplets and brs = broad singlet. ^{13}C NMR spectra were recorded on Bruker Advance[®] 500 (125 MHz) and Jeol Resonance ECX-400II (100 MHz) at R.T in CDCl_3 ; chemical shifts are calibrated relative to CDCl_3 ($\delta_{\text{C}} = 77.0\text{ ppm}$). The acquisition of High-resolution mass spectra (HRMS) was performed on Bruker daltronics microTOF-QII[®] spectrometer using ESI ionization. IR spectra were recorded on Perkin Elmer FT-IR spectrometer – spectrum two. Melting points were performed with *optimelt* automated melting point system.


The reactions were performed in a G-10 Borosilicate glass vial sealed with Teflon septum in Anton Paar Monowave 300 reactor[®], operating at a frequency of 2.455 GHz with continuous irradiation power of 0 to 300 W. Analysis of the reactions were done by thin layer chromatography (TLC). For this, Merck precoated silica gel TLC plates (Merck[®] 60F₂₅₄) were used. Aromatic aldehydes were purchased from locally available commercial sources and few of them from sigma Aldrich. All solvents; ethanol (EtOH), petroleum ether, ethyl acetate were purchased from locally available commercial sources and used as received. A variety of 5-aryl-1,3,4-thiadiazol-2-amines and isocyanides were prepared according to literature procedure.¹⁻³

1. R. S. Lamani, N. S. Shetty, R. R. Kamble and I. A. M. Khazi, *Eur. J. Med. Chem.*, 2009, **44**, 2828.
2. G. W. Gokel, R. P. Widera and W. P. Weber, *Organic syntheses*, 1976, **55**, 96.
3. a) I. Ugi and R. Meyr, *Organic Syntheses* 1973, **5**, 1060; b) R. Obrecht, R. Herrmann and I. Ugi, *Synthesis*, 1985, 400.


General procedure for the synthesis of imidazo[2,1-*b*][1,3,4]thiadiazole fused heterocycles *via* microwave assisted Groebke–Blackburn–Bienaymé Reaction.

5-Aryl-1,3,4-thiadiazol-2-amines **1a** (0.25 mmol), aromatic aldehyde **2a** (0.27 mmol) and isocyanide **3a** (0.30 mmol) were taken in G-10 glass vial capped with Teflon septum. After a pre-stirring of 1 or 2 minutes at RT, the vial was subjected to microwave irradiation with the initial ramp time of 1 minute at 60 °C. The temperature was then raised to 120 °C with the holding time of 5 minutes. The products were recrystallized using EtOH. Some of the viscous products (**4f**, **4i**, **4k**, **4m**) were purified by silica gel column chromatography (ethyl acetate/hexane). All the 16 compounds were confirmed by FTIR, ¹H NMR, ¹³C NMR and HRMS spectral analyses.


Spectral Data of all Compounds (4a-r)




***N*-tert-Butyl-2,6-diphenylimidazo[2,1-*b*][1,3,4]thiazol-5-amine (4a):** Yellow solid (98%), Mp 174-176 °C, IR (4000-600 cm⁻¹): $\nu_{\max}$ = 3431 (stretch NH), 1642 (stretch C=N), 1559 (bend NH), 1412, 1339 (stretch C-N). ¹H NMR (CDCl₃, 400 MHz): δ_{H} (ppm) 8.10-8.15 (m, 2H), 7.85-7.92 (m, 2H), 7.47-7.55 (m, 3H), 7.40 (t, 2H, J = 8 Hz), 7.22-7.28 (m, 1H), 3.16 (brs, NH), 1.20 (s, 9H). ¹³C NMR (CDCl₃, 100 MHz): δ_{C} (ppm) 167.1, 160.5, 140.8, 138.4, 135.1, 133.6, 131.5, 130.7, 130.4, 129.3, 128.2, 127.7, 126.9, 56.3, 30.3. HR-MS (ESI) for C₂₀H₂₀N₄S m/z calcd.: 349.1481; found: 349.1516 [M + H]⁺.




***N*-tert-butyl-6-(4-methoxyphenyl)-2-phenylimidazo[2,1-*b*][1,3,4]thiazol-5-amine (4b):** Yellow solid (90%), Mp 212-213 °C, IR (4000-600 cm⁻¹): $\nu_{\max}$ = 3411 (stretch NH), 1645 (stretch C=N), 1562 (bend NH), 1509, 1406, 1339 (stretch C-N). ¹H NMR (CDCl₃, 500 MHz): δ_{H} (ppm) 8.06 (d, 2H, J = 8.5 Hz), 7.83-7.91 (m, 2H), 7.46-7.54 (m, 3H), 6.94 (d, 2H, J = 8 Hz), 3.85 (s, 3H), 3.10 (brs, 1H), 2.17 (brs, 1H), 1.19 (s, 9H). ¹³C NMR (CDCl₃, 125 MHz): δ_{C} (ppm) 160.0, 158.5, 140.6, 138.3, 131.4, 130.7, 129.2, 128.1, 127.8, 126.7, 125.8, 113.6, 56.1, 55.2, 30.3. HR-MS (ESI) for C₂₁H₂₂N₄OS m/z calcd.: 379.1587; found: 379.1580 [M + H]⁺.




***N*-tert-butyl-2-(4-chlorophenyl)-6-phenylimidazo[2,1-*b*][1,3,4]thiazol-5-amine (4c):** Yellow solid (91%), Mp 219-221 °C, IR (4000-600 cm⁻¹): $\nu_{\max}$ = 3437 (stretch NH), 1639 (stretch C=N), 1559 (bend NH), 1409, 1336 (stretch C-N). ¹H NMR (CDCl₃, 500 MHz): δ_{H} (ppm) 8.11 (d, 2H, J = 10 Hz), 7.82 (d, 2H, J = 10 Hz), 7.48 (d, 2H, J = 10 Hz), 7.40 (t, 2H, J = 10 Hz), 7.24-7.29 (m, 1H), 3.15 (brs, NH), 2.17 (brs, enaminic proton), 1.19 (s, 9H). ¹³C NMR (CDCl₃, 100 MHz): δ_{C} (ppm) 159.2, 138.7, 137.7, 135.0, 129.6, 129.1, 128.3, 128.0, 127.0, 126.9, 126.81, 126.80, 56.4, 30.3. HR-MS (ESI) for C₂₀H₁₉ClN₄S m/z calcd.: 383.1091; found: 383.1125 [M + H]⁺.




***N*-tert-butyl-2-(4-chlorophenyl)-6-(4-nitrophenyl)imidazo[2,1-*b*][1,3,4]thiazol-5-amine (4d):** Yellow solid (90%), Mp 221-222 °C, IR (4000-600 cm⁻¹): $\nu_{\max}$ = 3434 (stretch NH), 2952 (sp²-CH), 2919 (sp³-CH), 1592 (stretch C=N), 1509 (asymm. stretch NO₂), 1468 (symm. stretch NO₂), 1327 (stretch C-N). ¹H NMR (CDCl₃, 400 MHz): δ_{H} (ppm) 8.42 (d, 2H, J = 12 Hz), 8.24 (d, 2H, J = 8 Hz), 7.82 (d, 2H, J = 8 Hz), 7.51 (d, 2H, J = 12 Hz), 3.15 (brs, NH), 1.10 (s, 9H). ¹³C NMR (CDCl₃, 100 MHz): δ_{C} (ppm) 160.4, 160.4, 146.2, 141.6, 141.6, 138.2, 129.8, 128.7, 128.1, 127.0, 123.7, 57.0, 30.4. HR-MS (ESI) for C₂₀H₁₈ClN₅O₂S m/z calcd.: 450.0761; found: 450.0750 [M + Na]⁺.




***N*-(2,6-dimethylphenyl)-2,6-diphenylimidazo[2,1-*b*][1,3,4]thiazol-5-amine (4e):** Yellow solid (87%), Mp 194-195 °C, IR (4000-600 cm⁻¹): $\nu_{\max}$ = 3417 (stretch NH), 1642 (stretch C=N), 1559 (bend NH), 1409 (stretch C-N). ¹H NMR (CDCl₃, 500 MHz): δ_{H} (ppm) 8.02 (d, 2H, J = 8 Hz), 7.69 (d, 2H, J = 7 Hz), 7.41-7.51 (m, 3H), 7.36 (t, 2H, J = 7.5 Hz), 7.22-7.27 (m, 1H), 6.99 (d, 2H, J = 7.5 Hz), 6.853 (t, 1H, J = 7 Hz), 5.29 (brs, NH), 2.17 (s, 6H). ¹³C NMR (CDCl₃, 100 MHz): δ_{C} (ppm) 161.0, 140.7, 140.5, 136.2, 133.9, 131.5, 130.3, 129.1, 129.1, 128.3, 128.1, 126.9, 126.7, 126.1, 124.7, 122.1, 18.6. HR-MS (ESI) for C₂₄H₂₀N₄S m/z calcd.: 397.1481; found: 397.1473 [M + H]⁺.



***N*-cyclohexyl-2,6-diphenylimidazo[2,1-*b*][1,3,4] thiazol-5-amine (4f):** Yellow solid (90%), Mp 211–213 °C, IR (4000–600 cm⁻¹): $\nu_{\max}$ = 3437 (stretch NH), 1639 (stretch C=N), 1556 (bend NH), 1412, 1339 (stretch C-N). ¹H NMR (CDCl₃, 500 MHz): δ_{H} (ppm) 8.04 (d, 2H, J = 8 Hz), 7.86–7.92 (m, 2H), 7.48–7.54 (m, 3H), 7.42 (t, 2H, J = 8 Hz), 7.24–7.28 (m, 1H) (merge with CDCl₃ region (7.260), 3.24–3.40 (m, 2H), 1.92–2.05 (m, 2H), 1.68–1.78 (m, 2H), 1.58–1.62 (m, 1H), 1.15–1.36 (m, 5H). ¹³C NMR (CDCl₃, 100 MHz): δ_{C} (ppm) 160.9, 160.8, 134.8, 134.0, 131.6, 130.7, 129.3, 128.7, 128.6, 126.9, 126.6, 125.9, 56.8, 34.2, 25.9, 25.0. HR-MS (ESI) for C₂₂H₂₂N₄S m/z calcd.: 375.1637; found: 375.1648 [M + H]⁺.




***N*-tert-butyl-6-(2-chloro-5-nitrophenyl)-2-(4-nitrophenyl)imidazo[2,1-*b*][1,3,4]thiadiazol-5-amine (4g):** Orange solid (85%), Mp 210–211 °C, IR (4000–600 cm⁻¹): $\nu_{\max}$ = 3428 (stretch NH), 1642 (stretch C=N), 1559 (bend NH), 1412 (asymm. stretch NO₂), 1341 (symm. stretch NO₂). ¹H NMR (CDCl₃, 400 MHz): δ_{H} (ppm) 8.55 (d, 1H, J = 2.4 Hz), 8.39 (dt, 2H, J = 8 Hz, J = 4 Hz), 8.17 (dd, 1H, J = 8 Hz, J = 4 Hz), 8.11 (dt, 2H, J = 8 Hz, J = 4 Hz), 7.65 (d, 1H, J = 8.8 Hz), 3.28 (brs, NH), 2.17 (brs, enaminic proton), 1.06 (s, 9H). ¹³C NMR (CDCl₃, 100 MHz): δ_{C} (ppm) 158.9, 149.6, 139.6, 135.9, 135.5, 135.4, 135.3, 131.0, 129.2, 127.8, 127.6, 124.7, 123.7, 56.0, 30.0. HR-MS (ESI) for C₂₀H₁₇ClN₆O₄S m/z calcd.: 495.0612; found: 473.0590 [M + Na]⁺.




2-(4-chlorophenyl)-*N*-(2,6-dimethylphenyl)-6-(4-methoxyphenyl)imidazo[2,1-*b*][1,3,4] thiazol-5-amine (4h): Yellow solid (85%), Mp 197–198 °C, IR (4000–600 cm⁻¹): $\nu_{\max}$ = 3414 (stretch NH), 1642 (stretch C=N), 1559 (bend NH), 1412, 1339 (stretch C-N). ¹H NMR (CDCl₃, 400 MHz): δ_{H} (ppm) 7.96 (d, 2H, J = 8 Hz), 7.62 (dt, 2H, J = 8 Hz, J = 4 Hz), 7.41 (dt, 2H, J = 8 Hz, J = 4 Hz), 6.99 (d, 2H, J = 8 Hz), 6.90 (d, 2H, J = 8 Hz), 6.84 (t, 1H, J = 8 Hz), 5.24 (brs, NH), 3.82 (s, 3H), 2.15 (s, 6H). ¹³C NMR (CDCl₃, 100 MHz): δ_{C} (ppm) 158.9, 137.7, 129.5, 129.3, 129.0, 127.9, 127.9, 127.9, 127.5,


122.1, 113.9, 55.3, 18.7. HR-MS (ESI) for $C_{25}H_{21}ClN_4OS$ m/z calcd.: 461.1197; found: 461.1210 $[M + H]^+$.



2,6-bis(4-chlorophenyl)-N-cyclohexylimidazo[2,1-*b*][1,3,4]thiadiazol-5-amine (4i): Yellow solid (92%), Mp 223-224 °C, IR (4000-600 cm^{-1}): ν_{max} = 3437 (stretch NH), 1639 (stretch C=N), 1559 (bend NH), 1409, 1336 (stretch C-N). 1H NMR ($CDCl_3$, 500 MHz): δ_H (ppm) 8.02 (d, 2H, J = 8.5 Hz), 7.82 (d, 2H, J = 8 Hz), 7.49 (d, 2H, J = 8.5 Hz), 7.37 (d, 2H, J = 8.5 Hz), 3.15-3.30 (m, 2H), 1.87-2.00 (m, 2H), 1.68-1.80 (m, 2H), 1.50-1.68 (m, 1H), 1.13-1.40 (m, 5H). ^{13}C NMR ($CDCl_3$, 125 MHz): δ_c (ppm) 159.7, 139.7, 137.7, 133.6, 133.1, 132.2, 126.6, 128.9, 128.6, 128.0, 127.1, 56.8, 33.9, 25.8, 24.8. HR-MS (ESI) for $C_{22}H_{20}Cl_2N_4S$ m/z calcd.: 465.0677; found: 465.0653 $[M + Na]^+$.




N-tert-butyl-6-(4-methoxyphenyl)-2-(4-nitrophenyl)imidazo[2,1-*b*][1,3,4]thiadiazol-5-amine (4j): Red solid (92%), Mp 210-211 °C, IR (4000-600 cm^{-1}): ν_{max} = 3431 (stretch NH), 1645 (stretch C=N), 1562 (asymm. stretch NO_2), 1415 (symm. stretch NO_2), 1338 (stretch C-N). 1H NMR ($CDCl_3$, 400 MHz): δ_H (ppm) 8.34-8.38 (m, 2H), 8.03-8.08 (m, 4H), 6.92-6.97 (m, 2H), 3.85 (s, 3H), 3.11 (brs, NH), 2.17 (brs, 1H), 1.20 (s, 9H). ^{13}C NMR ($CDCl_3$, 125 MHz): δ_c (ppm) 158.9, 157.2, 149.2, 140.6, 139.4, 136.4, 128.2, 127.5, 127.3, 126.1, 124.6, 113.7, 56.3, 55.3, 30.4. HR-MS (ESI) for $C_{21}H_{21}N_5O_3S$ m/z calcd.: 424.1438; found: 424.1463 $[M + H]^+$.




2-(4-chlorophenyl)-N-cyclohexyl-6-phenylimidazo[2,1-*b*][1,3,4] thiazol-5-amine (4k): Yellow solid (91%), Mp 201-202 °C, IR (4000-600 cm^{-1}): ν_{max} = 3423 (stretch NH), 1642 (stretch C=N), 1559 (bend NH), 1415, 1336 (stretch C-N). 1H NMR ($CDCl_3$, 500 MHz): δ_H (ppm) 8.03 (d, 2H, J = 7.5 Hz), 7.83 (d, 2H, J = 8.5 Hz), 7.49 (d, 2H, J = 8.5 Hz), 7.42 (t, 2H, J = 7.5 Hz), 7.24-7.28 (m, 1H), 3.23-3.36 (m, 2H), 2.170 (s, enaminic proton), 1.91-2.02 (m, 2H), 1.69-1.77 (m, 2H), 1.15-1.35 (m, 6H). ^{13}C NMR ($CDCl_3$, 100 MHz): δ_c (ppm) 169.7, 169.6, 134.7, 129.6, 129.1, 129.1, 128.9, 128.0, 126.7,


125.9, 125.9, 125.9, 56.8, 51.0, 34.2, 25.8, 24.8. HR-MS (ESI) for $C_{22}H_{21}ClN_4S$ m/z calcd.: 409.1248; found = 409.1225 $[M + H]^+$.



***N*-(2,6-dimethylphenyl)-2,6-bis(4-nitrophenyl)imidazo[2,1-*b*][1,3,4] thiazol-5-amine (4l):** Brown solid (85%), Mp 180-181 °C, IR (4000-600 cm^{-1}): ν_{max} = 3434 (stretch NH), 1639 (stretch C=N), 1553 (asymm. stretch NO_2), 1409 (symm. stretch NO_2), 1341 (stretch C-N). 1H NMR ($CDCl_3$, 500 MHz): δ_H (ppm) 8.32 (d, 2H, J = 8.4 Hz), 8.21 (d, 4H, J = 8.8 Hz), 8.17 (d, 2H, J = 8.6 Hz), 7.85 (d, 2H, J = 8.4 Hz), 7.04 (d, 2H, J = 7.4 Hz), 6.94 (t, 1H, J = 7.3 Hz), 5.41 (brs, NH), 2.17 (s, 6H). ^{13}C NMR ($CDCl_3$, 100 MHz): δ_c (ppm) 149.5, 146.2, 140.7, 140.1, 139.4, 139.4, 135.6, 129.3, 129.3, 127.6, 127.6, 126.3, 124.6, 123.9, 123.7, 18.7. Anal. Calcd for $C_{24}H_{18}N_6O_4S$; C, 59.25; H, 3.73; N, 17.27. Found: C, 59.29; H, 3.81; N, 17.31.




2-(4-chlorophenyl)-*N*-cyclohexyl-6-(4-methoxyphenyl)imidazo[2,1-*b*][1,3,4]thiazol-5-amine (4m): Yellow solid (86%), Mp 208-209 °C, IR (4000-600 cm^{-1}): ν_{max} = 3428 (stretch NH), 1636 (stretch C=N), 1565 (bend NH), 1409 (stretch C-N). 1H NMR ($CDCl_3$, 500 MHz): δ_H (ppm) 7.98 (d, 2H, J = 9 Hz), 7.82 (d, 2H, J = 8.5 Hz), 7.48 (d, 2H, J = 8.5 Hz), 6.97 (d, 2H, J = 9 Hz), 3.85 (s, 3H), 3.18-3.27 (bm, 2H), 1.92-1.98 (m, 2H), 1.71-1.78 (m, 2H), 1.175-1.325 (m, 6H). ^{13}C NMR ($CDCl_3$, 100 MHz): δ_c (ppm) 177.8, 177.8, 177.5, 161.6, 157.3, 142.0, 129.5, 127.9, 127.2, 113.9, 113.9, 113.9, 55.3, 55.3, 34.0, 25.8, 24.8. HR-MS (ESI) for $C_{23}H_{23}ClN_4OS$ m/z calcd.: 461.1173; found: 461.1136 $[M + Na]^+$.




***N*-tert-butyl-2-(4-chlorophenyl)-6-(4-methoxyphenyl)imidazo[2,1-*b*][1,3,4]thiazol-5-amine (4n):** Off white solid (85%), Mp 209-210 °C, IR (4000-600 cm^{-1}): ν_{max} = 3428 (stretch NH), 1642 (stretch


C=N), 1562 (bend NH), 1415, 1336 (stretch C-N). ^1H NMR (CDCl_3 , 400 MHz): δ_{H} (ppm) 8.05 (dt, 2H, $J = 8$ Hz, $J = 4$ Hz), 7.81 (dt, 2H, $J = 8$ Hz, $J = 4$ Hz), 7.48 (dt, 2H, $J = 8$ Hz, $J = 4$ Hz), 6.94 (dt, 2H, $J = 8$ Hz, $J = 4$ Hz), 3.85 (s, 3H), 3.09 (brs, NH), 2.18 (brs, enaminic proton), 1.19 (s, 9H). ^{13}C NMR (CDCl_3 , 100 MHz): δ_{C} (ppm) 158.7, 137.5, 137.5, 129.6, 129.2, 128.1, 127.9, 127.7, 127.7, 113.7, 56.2, 55.3, 30.4. Anal. Calcd for $\text{C}_{21}\text{H}_{21}\text{ClN}_4\text{OS}$; C, 61.08; H, 5.13; N, 13.57. Found: C, 61.13; H, 5.18; N, 13.63.




***N*-tert-butyl-2-(4-methoxyphenyl)-6-phenylimidazo[2,1-*b*][1,3,4]thiadiazol-5-amine (4o):** Off white solid (85%), Mp 204-204.5 °C, IR (4000-600 cm^{-1}): $\nu_{\text{max}} = 3443$ (stretch NH), 1640 (stretch C=N), 1563 (bend NH), 1467 (stretch C-N), 1414 (stretch C-N). ^1H NMR (CDCl_3 , 400 MHz): δ_{H} (ppm) 8.10 (d, 2H, $J = 8$ Hz), 7.80 (d, 2H, $J = 8.8$ Hz), 7.38 (t, 2H, $J = 8$ Hz), 7.22-7.26 (m, 1H), 6.99 (d, 2H, $J = 8.8$ Hz), 3.87 (s, 3H), 3.13 (brs, NH), 1.18 (s, 9H). ^{13}C NMR (CDCl_3 , 100 MHz): δ_{C} (ppm) 162.3, 160.4, 135.2, 135.2, 128.4, 128.2, 128.2, 126.8, 126.8, 126.8, 123.3, 114.7, 56.3, 55.6, 30.3. Anal. Calcd. for $\text{C}_{21}\text{H}_{22}\text{N}_4\text{OS}$; C, 66.64; H, 5.86; N, 14.80. Found: C, 66.70; H, 5.80; N, 14.86.



***N*-tert-butyl-2-(4-methoxyphenyl)-6-(4-nitrophenyl)imidazo[2,1-*b*][1,3,4]thiadiazol-5-amine (4p):** yellow solid (87%), Mp 227-227.5 °C, IR (4000-600 cm^{-1}): $\nu_{\text{max}} = 3447$ (stretch NH), 1643 (stretch C=N), 1567 (bend NH), 1412 (stretch C-N), 1340 (stretch C-N). ^1H NMR (CDCl_3 , 400 MHz): δ_{H} (ppm) 8.40 (d, 2H, $J = 8$ Hz), 8.22 (d, 2H, $J = 8$ Hz), 7.80 (d, 2H, $J = 8$ Hz), 7.00 (d, 2H, $J = 8$ Hz), 3.88 (s, 3H), 3.14 (brs, NH), 2.16 (s, enaminic proton), 1.20 (s, 9H). ^{13}C NMR (CDCl_3 , 100 MHz): δ_{C} (ppm) 162.6, 146.0, 141.9, 136.0, 128.6, 128.5, 126.8, 123.7, 122.8, 122.8, 114.8, 57.0, 55.7, 30.4. Anal. Calcd. for $\text{C}_{21}\text{H}_{21}\text{N}_5\text{O}_3\text{S}$; C, 59.56; H, 5.00; N, 16.54. Found: C, 59.65; H, 5.08; N, 16.61.



***N*-tert-butyl-6-(4-fluorophenyl)-2-phenylimidazo[2,1-*b*][1,3,4]thiadiazol-5-amine (4q):** yellow solid (89 %), Mp 233.7-233.9 °C, IR (4000-600 cm^{-1}): $\nu_{\text{max}} = 3446$ (stretch NH), 1639 (stretch C=N), 1559 (bend NH), ^1H NMR (CDCl_3 , 400 MHz): δ_{H} (ppm) 8.09-8.16 (m, 2H), 7.83-7.90 (m, 2H), 7.46-7.53 (m, 3H), 7.06 (t, 2H, $J = 8$ Hz), 3.07 (brs, NH), 2.16 (s, enaminic proton), 1.17 (s, 9H). ^{13}C NMR (CDCl_3 , 100 MHz): δ_{C} (ppm) 163.1, 160.7, 160.6, 131.6, 131.2, 131.2, 130.6, 130.2, 129.3, 129.1, 128.6, 128.5, 127.1, 126.8, 115.2, 115.0, 56.3, 30.3. Anal. Calcd. for $\text{C}_{20}\text{H}_{19}\text{FN}_4\text{S}$; C, 65.55; H, 5.23; N, 15.29. Found: C, 65.62; H, 5.32; N, 15.35.



N-tert-butyl-2-(4-chlorophenyl)-6-(4-fluorophenyl)imidazo[2,1-*b*][1,3,4]thiadiazol-5-amine (4r): yellow solid (86 %), Mp 229.0-229.2 °C, IR (4000-600 cm⁻¹): ν_{max} = 3431(stretch NH), 1648 (stretch C=N), 1564 (bend NH), 1349 (stretch C-N). ¹H NMR (CDCl₃, 400 MHz): δ_{H} (ppm) 8.09-8.15 (m, 2H), 7.80 (d, 2H, J = 8.8 Hz), 7.47 (d, 2H, J = 8.4 Hz), 7.07 (t, 2H, J = 8.8 Hz), 3.07 (brs, NH), 2.17 (s, enaminic proton), 1.18 (s, 9H). ¹³C NMR (CDCl₃, 100 MHz): δ_{C} (ppm) 163.2, 160.7, 159.3, 140.7, 137.7, 131.1, 131.1, 129.6, 129.1, 128.6, 128.5, 128.0, 115.2, 115.0, 56.4, 30.3. Anal. Calcd. for C₂₀H₁₈ClFN₄S; C, 59.92; H, 4.53; N, 13.98. Found: C, 59.99; H, 4.62; N, 14.06.

Green Metrics Calculations

$$\% \text{ Atom Efficiency} = \frac{(\text{Mol Wt. of desired product})}{(\text{Mol Wt. of all reagents})} \times 100$$

$$\% \text{ Carbon Efficiency} = \frac{\text{Mass of carbon in product}}{\text{Total mass of carbon in key reactants}} \times 100$$


$$\text{Reaction Mass Efficiency} = \frac{(\text{Mass of Isolated Product})}{(\text{Total mass of reactants used in the reaction})} \times 100$$

$$E - \text{Factor} = \frac{\text{Mass of Total Waste}}{\text{Mass of crude Product}}$$

$$\text{Process Mass Intensity (PMI)} = \frac{\text{Total mass used in process}}{\text{Mass of product}}$$

Comparison of present protocol for the synthesis of *N-tert*-butyl-2,6-diphenylimidazo[2,1-*b*][1,3,4]thiadiazol-5-amine 4a with reported methods

A) Calculation for the synthesis of *N-tert*-butyl-6-phenylimidazo[2,1-*b*][1,3,4]thiadiazol-5-amine



Raw Materials Used		Crude Product and Waste	
1,3,4-Thiadiazole-5-amine (1.0 eq.)	101.13 mg	Product	207.0 mg
<i>tert</i> -butylisocyanide (1.2 eq.)	99.75 mg	Waste	2766 mg
Benzaldehyde (1.2 eq.)	127.3 mg		
HClO ₄ (5%)	5.02 mg		
Trifluoroethanol (TFE)	2640 mg		
Total	2973 mg	Total	2973 mg


E-Factor (E) = (2766 mg of waste produced / 207.0 mg of crude product) = 13.36.

Mass Intensity = (2973 mg of raw material used / 207.0 mg of crude product) = 14.36.

Considerations:

1. Calculation did not consider organic solvents used for work-up and column chromatography.

B) Calculation for the synthesis of 2-(4-(3-methoxybenzyl)piperazin-1-yl)-*N*-*tert*-butyl-6-(4-fluorophenyl)imidazo[2,1-*b*][1,3,4]thiadiazol-5-amine.



Raw Materials Used		Crude Product and Waste	
5-(4-(3-methoxybenzyl)piperazin-1-yl)-1,3,4-thiadiazole-5-amine (1.0 eq.)	305.4 mg	Product	415.5 mg
<i>tert</i> -butylisocyanide (1.0 eq.)	83.13 mg	Waste	1759.8mg
4-Fluoro benzaldehyde (1.0 eq.)	106.12 mg		
TMSCl	108.64 mg		
Acetonitrile	1572 mg		
Total	2175mg	Total	2175 mg


E-Factor (E) = (1759 mg of waste produced / 415.5 mg of crude product) = 4.23.

Mass Intensity = (2175 mg of raw material used / 415.5 mg of crude product) = 5.23.

Considerations:

1. Calculation did not consider organic solvents used for work-up and column chromatography.

C) Calculation for the synthesis of *N*-*tert*-butyl-2,6-diphenylimidazo[2,1-*b*][1,3,4]thiadiazol-5-amine **4a**




Raw Materials Used		Crude Product and Waste	
5-Phenyl-1,3,4-thiadiazole-5-amine (1.0 eq.)	177.23 mg	Product	341.5 mg
<i>tert</i> -butylisocyanide (1.2 eq.)	99.75 mg	Waste	52.2mg
Benzaldehyde (1.1 eq.)	116.7 mg		
Total	393.7mg	Total	393.7 mg


E-Factor (E) = (52.2 mg of waste produced / 341.5mg of crude product) = 0.153.

Mass Intensity = (393.7 mg of raw material used / 341.5 mg of crude product) =1.153.


Copies of ^1H , ^{13}C NMR of all compounds.


N-*tert*-butyl-2,6-diphenylimidazo[2,1-*b*][1,3,4]thiazol-5-amine (4a)







N-*tert*-butyl-6(4-methoxyphenyl)-2-phenylimidazo[2,1-*b*][1,3,4]thiazol-5-amine (4b)







N-*tert*-butyl-2-(4-chlorophenyl)-6-phenylimidazo[2,1-*b*][1,3,4]thiazol-5-amine (4c)







N-*tert*-butyl-2(4-chlorophenyl)-6-(4-nitrophenyl)imidazo[2,1-*b*][1,3,4]thiazol-5-amine (4d):







N-(2,6-dimethylphenyl)-2,6-diphenylimidazo[2,1-*b*][1,3,4]thiazol-5-amine (4e)







N-cyclohexyl-2,6-diphenylimidazo[2,1-*b*][1,3,4]thiazol-5-amine (4f)





***N*-tert-butyl-6-(2-chloro-5-nitrophenyl)-2-(4-nitrophenyl)imidazo[2,1-*b*][1,3,4]thiadiazol-5-amine (4g)**







2-(4-chlorophenyl)-N-(2,6-dimethylphenyl)-6-(4-methoxyphenyl)imidazo[2,1-b][1,3,4]thiazol-5-amine (4h)







2,6-bis(4-chlorophenyl)-*N*-cyclohexylimidazo[2,1-*b*][1,3,4]thiadiazol-5-amine (4i)







***N*-tert-butyl-6-(4-methoxyphenyl)-2-(4-nitrophenyl)imidazo[2,1-*b*][1,3,4]thiadiazol-5-amine (4j)**







2-(4-chlorophenyl)-*N*-cyclohexyl-6-phenylimidazo[2,1-*b*][1,3,4]thiazol-5-amine (4k)







***N*-(2,6-dimethylphenyl)-2,6-bis(4-nitrophenyl)imidazo[2,1-*b*][1,3,4]thiazol-5-amine (4l)**







2-(4-chlorophenyl)-*N*-cyclohexyl-6-(4-methoxyphenyl)imidazo[2,1-*b*][1,3,4]thiazol-5-amine (4m)







***N*-tert-butyl-2-(4-chlorophenyl)-6-(4-methoxyphenyl)imidazo[2,1-*b*][1,3,4]thiazol-5-amine (4n)**







***N*-tert-butyl-2(4-methoxyphenyl)-6-phenylimidazo[2,1-*b*][1,3,4]thiadiazol-5-amine (4o):**







***N*-tert-butyl-2(4-methoxyphenyl)-6-(4-nitrophenyl)imidazo[2,1-*b*][1,3,4]thiadiazol-5-amine (4p):**





***N*-tert-butyl-6-(4-fluorophenyl)-2-phenylimidazo[2,1-*b*][1,3,4]thiadiazol-5-amine (4q):**





N-tert-butyl-2-(4-chlorophenyl)-6-(4-fluorophenyl)imidazo[2,1-*b*][1,3,4]thiadiazol-5-amine (4r):

